Unlock the Phenome
While chimeric antigen receptor (CAR) T-cell therapies have significantly improved outcomes in hematological malignancies, attempts to translate this success to solid tumors have presented several challenges, such as inadequate efficacy and unacceptable toxicity. Researchers are continuously identifying new targets to overcome these challenges. However, in cell line development, translating their findings into viable, testable products …
How Function-First CAR-T Discovery Could Accelerate the Bench to Bedside Journey Read More »
We’re excited to announce that from December 13-16, Bruker Cellular Analysis will be an exhibitor at this year’s Antibody Engineering & Therapeutics Conference in San Diego. This premier event is dedicated to showcasing the latest advancements in antibody engineering, design, and selection. With a focus on diverse topics such as Neurodegenerative Diseases, Tumor Microenvironment in …
Immunotoxin therapies have substantial potential and have already been demonstrated to improve outcomes in several types of cancers, but their efficacy has been limited. Cancer and tumor-associated cells oftentimes secrete proteins or express receptors that dampen immune activity to create an immunosuppressive environment that hinders therapeutic efficacy. Molecules that stimulate immune activity can help to …
In the field of oncology, chimeric antigen receptor (CAR)-T cell therapy is a focal point of innovative research that has the potential to revolutionize cancer treatment. In our new eBook, “Creating the World’s First On-Chip CAR Library: How Cutting Edge Thinking and Technology Are Transforming the Cancer Treatment Landscape,” we offer you the opportunity to …
New eBook: Unveiling a Breakthrough in Cancer Treatment Read More »
The Protein & Antibody Engineering Summit (PEGS) International Conference, set to take place from November 14-16th at the Lisbon Congress Center in Lisbon, Portugal, is the largest protein & antibody engineering event in Europe, which has been described as “the best biologics technology meeting in Europe.” The team from Bruker Cellular Analysis will be at …
Unveiling the Future of Protein and Antibody Research: The PEGS International Conference Read More »
Bruker Cellular Analysis will be participating in the upcoming Society for Immunotherapy of Cancer (SITC) Conference, scheduled to take place on November 1-5 at the San Diego Convention Center. This conference stands as a leading global event that unites experts from the field of immunotherapy to advance the science, discover breakthroughs, and educate the world …
Researchers have used Bruker Cellular Analysis’ Optofluidic technology to establish the fastest high-resolution workflow for the discovery and engineering of VHH antibodies yet. Scientists developed a novel application leveraging Bruker’s optofluidic Beacon® platform to detect IgG2/3 antibodies from activated memory B cells derived from alpaca peripheral blood samples. B cells secreting PSMA-specific antibodies were recovered …
Although cellular immunotherapy can achieve good outcomes, only a small proportion of cancer patients are being treated via this approach, with extremely long waitlists. Furthermore, applying centralized manufacturing workflows to individualized products results in complex logistics, creating laborious and non-standardized processes that elevate drug costs. In this upcoming webinar on Thursday, October 26, 10:00-11:00 AM …
Upcoming Webinar: How to Speed Up Cell Therapy Development Processes Read More »
Scientists often use classical immunization strategies and hybridoma technologies to generate antibodies. However, when producing antibodies against poorly immunogenic targets, such as membrane proteins with short extracellular domains, these approaches achieve limited antibody diversity, making it difficult for scientists to select good candidates for pharmaceutical development. Innovative approaches that combine RNA immunization and single cell …
Upcoming Webinar: Accelerating Antibody Discovery for Difficult Targets Read More »
Unlock the future of antibody discovery with Opto® B Discovery on the Beacon® platform. This cutting-edge technology streamlines the process, drastically reducing time and cost. This state-of-the-art workflow leverages up to 4 optofluidic chips, characterizing single B cells quickly and efficiently. With the Opto® B Discovery workflow, the Beacon system can significantly speed up your …
In the dynamic world of science and technology, Bruker Cellular Analysis is at the forefront, driving advancements in functional cell biology to improve human health. Our goal is to empower scientists to maximize the potential of every cell through pioneering optofluidic and proteomic technologies. We are excited to share our latest innovations and collaborations at …
In a significant development, we are pleased to introduce Meteor™ chips on the IsoSpark™ platform, marking a major step forward in high-throughput, quantitative, and automated bulk proteomics. This advancement promises to simplify research processes and expedite scientific progress. Meteor chips on the IsoSpark platform: The Advantages Automated Analysis and User-Friendly Meteor chips simplify proteomic workflows. …
Biotherapeutics comprise a large portion of the treatment options for a wide range of conditions and account for almost half of drugs approvals in 2022. However, the pace of new biologic development has not grown in recent years in part because of the increasing complexity of drug targets and desired performance of these drugs. To …
In a groundbreaking study, researchers at the University of Pennsylvania have identified a novel approach for advancing the effectiveness of CAR-T cell therapy for treating multiple myeloma (MM), a challenging form of cancer. In particular, the study investigates the phenomenon of CAR-T cell suppression, which often leads to relapses in MM patients treated with BCMA-specific …
The world’s battle against emerging diseases and endemic threats demands rapid, effective solutions. The recent evolution of viruses like SARS-CoV-2 underscores the need for innovative antibody discovery methods that can keep pace with mutations. Introducing the Bruker Cellular Analysis Beacon® optofluidic system, a revolutionary tool that’s reshaping the fight against diseases. In our latest Application …
The convergence of optofluidics and proteomic barcoding technologies marks a significant milestone in the evolution of cancer immunotherapy research. These cutting-edge tools empower scientists to unravel the complexities of immune responses, cellular behaviors, and functional proteomics with unprecedented speed and precision. As the pursuit of personalized medicine gains momentum, these technologies offer promise in guiding …
Advancing Cancer Immunotherapy with Optofluidics and Proteomic Barcoding Technologies Read More »
In both research and clinical settings, the ability to identify which immune cells in a person’s body contribute to either cancer progression or clearance and their target specificity is of critical importance. Moreover, a more thorough understanding of the biological properties of T cells that correlate with clinical outcome is required and can help guide …
Over the last few decades, the scientific community has turned its gaze towards a promising field in the fight against cancer – immunology. The idea of harnessing the power of the immune system and functional cytokines to develop cancer treatments has been gaining traction.1 However, the cancer immunotherapy development pipeline is a long and winding …
Cancer Immunotherapy Spotlight: How Functional Analysis is Shaping the Future Read More »
Bruker Cellular Analysis is looking forward to attending the 8th CAR-TCR Summit, the world’s pre-eminent industry-leading comprehensive forum that unites the global cell therapy community across a variety of cell types. From August 29 – September 1st in Boston, MA, this conference will feature groundbreaking presentations, panel discussions, and poster sessions focused on CAR-T and …
The use of therapeutic cancer vaccines is a promising immunotherapy option designed to activate immune effectors against tumor antigens. Research into the use of mRNA as a cancer vaccine platform spans back to the 1990s. Unfortunately, the short half-life of mRNA results in transient protein expression that limits its effectiveness as a cancer vaccine. This …
The key to developing successful immunotherapy treatments lies in harnessing the power of our immune system, specifically by profiling individual T cell function. With advancements in areas like cancer immunotherapy, vaccine development, infectious disease, autoimmune disease, and organ transplantation, there is a pressing need for new biomarkers that can identify and characterize the most potent …
With an estimated $12 billion in worldwide sales1, ion channel antibodies are the third best-selling group of prescribed drugs and a huge potential growth area. But the inefficiencies of traditional antibody discovery processes can oftentimes block the road to market approval in early-stage development. Methods such as hybridoma and B cell sequencing comprise multiple manual time-consuming …
Put Your Best Cells Forward: Overcoming the Challenges of Ion Channel Antibody Discovery Read More »
Immune checkpoint inhibitor therapy (ICT) is a form of cancer immunotherapy that specifically targets immune checkpoint regulators that tumor cells use to evade immune responses. Though ICT treatments have shown promising results in patients with previously “incurable” cancers, up to 50% of patients continue to remain unresponsive to the therapy. To identify the mechanisms driving …
As next-generation precision medicine grows, so does the need for broader accessibility to cutting-edge technologies. To meet this demand, Bruker Cellular Analysis has introduced the Beacon Quest™ optofluidic system, a two-chip optofluidic system that features Opto T Cell Profiling workflows for immunotherapy translational research, Opto Plasma B Discovery workflow and Opto Memory B Discovery workflows …
Cancer treatments have come a long way in recent years, and adoptive cell therapy (ACT) is at the forefront of this transformation. With promising therapies such as CAR-T, CAR-NK, TCR-T and TIL, ACT is providing renewed hope and improved outcomes for patients. Still, there’s more work to be done. To fully comprehend the potency of …
Biologics have immense commercial potential. However, developing successful candidates can feel like looking for a needle in a haystack. Research, development, manufacturing, and clinical testing are limited by substantial time and cost considerations. But what if you could identify a higher quantity of quality hits in a fraction of the time and with a fraction …
While genomic sequencing has been instrumental in revealing genetic mutations that promote the development of cancerous cells, additional research techniques are necessary to fully understand how gene mutations affect cell function and signaling networks, in turn helping researchers uncover the significant mechanisms driving carcinogenesis. The complexity of intracellular signaling in cancer cells makes it difficult …
Monoclonal antibodies are a powerful weapon in the fight against pathogens. However, infectious diseases can quickly develop variants with increased transmissibility or deadliness. In order to keep up with these emerging variants, scientists must be able to quickly identify effective antibodies. The COVID-19 pandemic has been a prime example of this challenge. The SARS-CoV-2 virus …
Every year, head and neck cancers (HNC) claim thousands of lives, with over 54,000 cases diagnosed annually in the United States alone, resulting in approximately 11,000 fatalities.1 HNCs are particularly difficult to treat—about one in three patients will not survive five years after diagnosis, despite a range of treatment options including surgery, radiation, chemotherapy, and …
Cancer has long been one of the most challenging diseases to treat as traditional treatments, like chemotherapy and radiation, can be harsh on the body and are not always successful. However, recent advancements in the field of immunotherapy have improved anti-cancer treatments; one of the more promising immunotherapy approaches being Immune Checkpoint Blockade (ICB) therapy. …